Taking Aim at ALK Across the Blood–Brain Barrier
- 1 April 2013
- journal article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 8 (4), 389-390
- https://doi.org/10.1097/jto.0b013e3182864e7c
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- High-Dose Pemetrexed in Combination with High-Dose Crizotinib for the Treatment of Refractory CNS Metastases in ALK-Rearranged Non–Small-Cell Lung CancerJournal of Thoracic Oncology, 2013
- Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancerAnnals Of Oncology, 2013
- Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung CancerJournal of Thoracic Oncology, 2012
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 studyThe Lancet Oncology, 2012
- Rapid Radiographic and Clinical Improvement After Treatment of a MET-Amplified Recurrent Glioblastoma With a Mesenchymal-Epithelial Transition InhibitorJournal of Clinical Oncology, 2012
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisThe Lancet Oncology, 2011
- CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor CrizotinibJournal of Clinical Oncology, 2011
- Biomarkers Are Here to Stay for Clinical Research and Standard CareJournal of Thoracic Oncology, 2010
- Activity of Pemetrexed on brain metastases from Non-Small Cell Lung CancerLung Cancer, 2010
- Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrierAnti-Cancer Drugs, 2007